The Applicability of the International Staging System in Chinese Patients with Multiple Myeloma Receiving Bortezomib or Thalidomide-Based Regimens as Induction Therapy: A Multicenter Analysis

Figure 3

Overall survival for 709 patients with newly diagnosed symptomatic multiple myeloma according to the ISS stages I, II, and III, who were treated with bortezomib-based treatment as first-line therapy.